The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors
IntroductionHormonal therapy (HT) blocks the hormone-mediated growth signal dramatically reducing estrogenic levels with aromatase inhibitors (AIs) becoming a crucial component of the treatment mainstay in patients with early breast cancer (BC). Postmenopausal BC patients receiving HT present with a...
Main Authors: | Antonio Galvano, Valerio Gristina, Dalila Scaturro, Tancredi Didier Bazan Russo, Sofia Tomasello, Fabio Vitagliani, Federica Carità, Maria La Mantia, Fabio Fulfaro, Viviana Bazan, Giulia Letizia Mauro, Antonio Russo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1297950/full |
Similar Items
-
The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study
by: Rikke Viggers, et al.
Published: (2022-01-01) -
Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center
by: Saad Hajeri, BDS, et al.
Published: (2022-09-01) -
Aromatase inhibitors in the treatment of endometriosis
by: Radosław Słopień, et al.
Published: (2016-03-01) -
Comparison of antiresorptive agents in the treatment of osteoporosis in older adults
by: Zeynel Abidin Öztürk, et al.
Published: (2022-09-01) -
The Role of Aromatase Inhibitors in Male Prolactinoma
by: Amit Akirov, et al.
Published: (2023-02-01)